3 Medical Supplies Stocks That Beat the Market Despite Macro Headwinds

Three large healthcare distributors have delivered outsized stock returns driven by operational execution rather than macro tailwinds: Cardinal Health posted fiscal Q1 2026 revenue up 22% to $64.0B with double‑digit operating earnings growth across all segments, $1.3B adjusted free cash flow and $500M returned to shareholders (fiscal 2026 EPS est. +$0.07 to $9.86). McKesson reported fiscal Q2 2026 revenue up 10% to $103B and 39% adjusted EPS growth, generated $2.2B free cash flow, returned $907M to shareholders and raised FY adjusted EPS guidance to $38.35–$38.85 (est. +$0.37 to $38.61). Cencora delivered fiscal Q4 2025 revenue +6% and 15% adjusted EPS growth with operating income up 20%, generated $3B adjusted free cash flow in FY2025, returned nearly $900M to shareholders and plans ~$1B of distribution/cold‑chain investment through 2030; recent M&A (Solaris Health pending for Cardinal, Retina Consultants for Cencora) and tariff/supply‑chain considerations are highlighted as execution risks and opportunities.

Analysis

Winners are CAH, MCK and COR as specialty mix, scale and automation convert volume into margin; CAH’s $1.3bn adj FCF, MCK’s $2.2bn and COR’s $3bn give flexibility for buybacks/M&A. Losers are smaller regional distributors and commoditized medical product OEMs that cannot absorb tariff-driven input-cost shocks or compete on cold-chain/specialty logistics. The GLP-1/specialty wave and oncology multispecialty growth suggest demand-side concentration: a 10–30% mix increase in specialty drugs can drive disproportionate profit upside for scale players.

Tail risks include rapid policy action (Medicare negotiation or a 10–20% reimbursement cut shock), loss of a top-5 customer (as COR experienced), large tariff re-escalation, or major cyber/operational outage; any of these could compress EPS by 10–30% in 1–3 quarters. Near-term (days/weeks) volatility will cluster around earnings and deal closes (Solaris for CAH); medium-term (3–12 months) outcomes hinge on integration and specialty mix retention; long-term (1–5 years) depends on ROIC from cold-chain capex (~$1bn through 2030 at COR).

Trade implications: establish differentiated exposure — overweight MCK (best-in-class cash conversion) with a 2–3% portfolio long, add CAH 1–2% for turnaround optionality, and a tactical 1% position in COR to play cold-chain secular growth. Pair idea: long MCK (2%) / short Owens & Minor (OMI, 1%) to express scale/portfolio quality vs regional distributor risk. Use defined-risk options: buy 3–6 month call spreads ~10–15% OTM on MCK and CAH to capture earnings-led re-rating, and buy 6-month puts as insurance if CMS pricing headlines rise.

Consensus is underestimating concentration risk: specialty revenue is sticky only if payer/reimbursement frameworks remain stable — a 10% policy-driven margin hit would be underpriced. The market may be underpricing capex risk (COR’s $1bn) turning into a ROIC drag if specialty volumes plateau; historically (post-2015 distribution consolidation) scale led to durable outperformance, but only after multi-quarter integration wins — so watch execution metrics (gross-to-net, specialty fill rates) rather than headlines.

Key Decisions for Investors

• Establish a 2–3% long position in MCK within the next 2–4 weeks ahead of continued earnings momentum; target a 15–20% upside take-profit or trim after EPS guidance is raised again, cut to 1% if negative organic growth is reported.
• Add a 1–2% speculative long in CAH to play turnaround optionality and Solaris accretion; prefer 3–6 month 10–15% OTM call spreads to limit premium paid, exit on a >20% move or after Solaris deal closes/integration update.
• Initiate a 1% long position in COR for structural cold-chain exposure but hedge with a 6–9 month 5–10% OTM put if CMS drug-pricing legislation gains traction; reduce to zero if COR reports loss of another large account or capex overruns >20% vs plan.
• Enter a pair trade: long MCK (2%) / short OMI (Owens & Minor, 1%) to capture scale vs regional weakness; unwind if the spread compresses by 50% or if OMI reports meaningful specialty contract wins.
• Monitor specific catalysts in next 30–90 days: (1) CAH Solaris closing date, (2) CMS/legislative drug-pricing announcements, (3) quarterly specialty-volume metrics (GLP-1 and oncology), and (4) tariff updates — take risk-off if any deliverable indicates >10% downside to consensus EPS.